BR112016011091A2 - sequência de endolisina kz144 modificada - Google Patents

sequência de endolisina kz144 modificada

Info

Publication number
BR112016011091A2
BR112016011091A2 BR112016011091A BR112016011091A BR112016011091A2 BR 112016011091 A2 BR112016011091 A2 BR 112016011091A2 BR 112016011091 A BR112016011091 A BR 112016011091A BR 112016011091 A BR112016011091 A BR 112016011091A BR 112016011091 A2 BR112016011091 A2 BR 112016011091A2
Authority
BR
Brazil
Prior art keywords
sequence
polypeptides
present
nucleic acids
relates
Prior art date
Application number
BR112016011091A
Other languages
English (en)
Other versions
BR112016011091B1 (pt
Inventor
Stüer Heike
Sterner Reinhard
Miller Stefan
Original Assignee
Lysando Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lysando Ag filed Critical Lysando Ag
Publication of BR112016011091A2 publication Critical patent/BR112016011091A2/pt
Publication of BR112016011091B1 publication Critical patent/BR112016011091B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2462—Lysozyme (3.2.1.17)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

a presente invenção refere-se a polipeptídios compreendendo uma sequência de aminoácidos apresentando identidade de sequência de pelo menos aproximadamente 90% com a sequência da seq id no: 1. os referidos polipeptídios de preferência degradam o peptidoglicano de bactérias gram-negativas, em particular de bactérias pseudomonas e/ou campylobacter. além disso, a presente invenção refere-se a ácidos nucléicos codificando tais polipeptídios, vetores compreendendo tais ácidos nucléicos, e células hospedeiras correspondentes. por fim, a presente invenção refere-se a composições compreendendo tais polipeptídios, ácidos nucléicos, vetores e/ou células hospedeiras de acordo com a presente invenção.
BR112016011091-9A 2013-11-14 2014-11-14 Sequência de endolisina kz144 modificada BR112016011091B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2013/073869 WO2015070911A1 (en) 2013-11-14 2013-11-14 Modified kz144 endolysin sequence
EPPCT/EP2013/073869 2013-11-14
PCT/EP2014/074671 WO2015071436A1 (en) 2013-11-14 2014-11-14 Modified kz144 endolysin sequence

Publications (2)

Publication Number Publication Date
BR112016011091A2 true BR112016011091A2 (pt) 2017-12-05
BR112016011091B1 BR112016011091B1 (pt) 2024-02-06

Family

ID=49582760

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016011091-9A BR112016011091B1 (pt) 2013-11-14 2014-11-14 Sequência de endolisina kz144 modificada

Country Status (10)

Country Link
US (1) US10184120B2 (pt)
JP (1) JP6745720B2 (pt)
KR (1) KR102302044B1 (pt)
CN (1) CN105793419B (pt)
AU (1) AU2014350104B2 (pt)
BR (1) BR112016011091B1 (pt)
CA (1) CA2929686C (pt)
EA (1) EA035959B1 (pt)
MX (1) MX2016006277A (pt)
WO (2) WO2015070911A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2998484A1 (en) 2015-09-17 2017-03-23 Contrafect Corporation Use of lysin to restore/augment antibacterial activity in the presence of pulmonary surfactant of antibiotics inhibited thereby
CA3022334A1 (en) * 2016-04-28 2017-11-02 Lysando Ag Antimicrobial agents against salmonella bacteria
US11208646B2 (en) 2016-05-27 2021-12-28 Sasinapas Co., Ltd. Endolysin variant
WO2018100408A1 (en) 2016-11-30 2018-06-07 Sasinapas Co.,Ltd. Modified peptides
MX2019011808A (es) * 2017-04-03 2020-01-09 Sasinapas Co Ltd Endolisinas de gram-negativas modificadas.
CN111304181B (zh) * 2020-02-17 2021-11-23 华东理工大学 一种基因工程改造后的副溶血性弧菌噬菌体裂解酶及其制备方法和应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1289092C (en) * 1987-01-15 1991-09-17 Robert A. Hallewell Thermostable human cu/zn superoxide dismutase muteins
EP0285123A3 (en) 1987-04-03 1989-02-01 Stabra AG A method for complete mutagenesis of nucleic acids
ZA936811B (en) * 1992-10-28 1995-03-15 Upjohn Co Somatotropin modifications
JPH08127540A (ja) * 1994-09-09 1996-05-21 Takeda Chem Ind Ltd 抗潰瘍医薬
NO2185699T3 (pt) * 2007-08-22 2018-04-21
GB0815484D0 (en) 2008-08-26 2008-10-01 Univ Leuven Kath Antibacterial agents
BRPI1015203B1 (pt) 2009-06-26 2021-06-01 Lysando Ag Proteína de fusão composta por uma endolisina e uma extensão de peptídeo anfifática, usos da mesma e composição farmacêutica que compreende a dita proteína
KR20170024129A (ko) * 2009-06-26 2017-03-06 카톨리에케 유니버시테이트 루벤 항균제
CN102575240B (zh) * 2009-08-24 2016-01-13 勒芬天主教大学，K.U.勒芬R&D 新的细胞内溶素OBPgpLYS
CN103119158B (zh) * 2010-04-27 2015-04-08 莱桑多公司 减少生物膜的方法
GB201018518D0 (en) * 2010-11-03 2010-12-15 Univ Leuven Kath Novel endolysin
EP2468856A1 (en) 2010-12-23 2012-06-27 Lysando Aktiengesellschaft Antimicrobial Agents
KR20130142837A (ko) * 2012-06-20 2013-12-30 한국외국어대학교 연구산학협력단 슈도모나스 에루기노사의 박테리오파아지 및 그 용도

Also Published As

Publication number Publication date
KR102302044B1 (ko) 2021-09-15
JP2016537979A (ja) 2016-12-08
CA2929686A1 (en) 2015-05-21
NZ719338A (en) 2022-03-25
BR112016011091B1 (pt) 2024-02-06
WO2015071436A1 (en) 2015-05-21
WO2015070911A1 (en) 2015-05-21
CN105793419B (zh) 2021-06-01
JP6745720B2 (ja) 2020-08-26
US10184120B2 (en) 2019-01-22
US20160281074A1 (en) 2016-09-29
AU2014350104A1 (en) 2016-05-12
AU2014350104B2 (en) 2020-03-05
EA201691004A1 (ru) 2017-01-30
MX2016006277A (es) 2017-01-05
EA035959B1 (ru) 2020-09-07
KR20160085342A (ko) 2016-07-15
CA2929686C (en) 2023-08-08
CN105793419A (zh) 2016-07-20

Similar Documents

Publication Publication Date Title
BR112016011091A2 (pt) sequência de endolisina kz144 modificada
BR112016011095A2 (pt) Sequência de endolisina el188 modificada
BR112017022298A2 (pt) geranilgeranil pirofosfato sintase
BR112018010805A2 (pt) mutantes de proteína f de rsv
MY176331A (en) Carbohydrate degrading polypeptide and uses thereof
BR112017015567A2 (pt) proteína gl de citomegalovírus recombinante ou fragmento de formação de complexo da mesma, complexo de citomegalovírus, ácido nucleico isolado, célula hospedeira, e, composição imunogênica
BR112017017884A2 (pt) switches transcricionais desencadeados por ligação e métodos de uso dos mesmos
BR112016002614A8 (pt) Imunocitoquina, ácido nucleico, vetor, célula hospedeira e composição farmacêutica
BR112017020308A2 (pt) udp-glicosiltransferases
ECSP15042898A (es) Péptidos y composiciones para el tratamiento de daño articular
WO2014202616A3 (en) Rasamsonia gene and use thereof
BR112012033404A2 (pt) polipetídeo tendo ou auxiliando a atividade de degradação de material de carboidratos e uso dos mesmos.
WO2014202622A3 (en) Rasamsonia gene and use thereof
BR112015013387B8 (pt) Proteínas tipo coiled-coil modificadas possuindo propriedades melhoradas
EA201401211A1 (ru) Улучшенные варианты фермента химозина
BR112015017797A2 (pt) celobio-hidrolase termoestável
EA201691981A1 (ru) Улучшенные транспортные молекулы модулярного антигена и их применение
BR112012033714A2 (pt) polipeptídeo com atividade de acetil xilano esterase e seus usos.
BR112012033701A2 (pt) polipeptídeo tendo atividade de degradação de carbohidrato e seus usos
MY195726A (en) Steviol Glycoside Transport
WO2017060318A3 (en) Kaurenoic acid hydroxylases
MY187334A (en) Xylanase
BR112018003925A2 (pt) composição líquida de detergência compreendendo uma protease e uma lipase
AR101146A1 (es) Proteína con actividad xilanasa
BR112012033396A2 (pt) Polipetídeo tendo atividade swollenin e seus usos.

Legal Events

Date Code Title Description
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 14/11/2014, OBSERVADAS AS CONDICOES LEGAIS